Cardium Therapeutics has built a name for itself by capturing innovative biomedical technologies that emerge in the health sciences and regenerative medicine space, while simultaneously developing its own technology portfolio. By focusing on underserved demand and products/business opportunities with a … Continue reading →

In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given … Continue reading →

Cardium Therapeutics is currently exhibiting its new FDA-cleared Excellagen® professional-use, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds at the 2012 Spring Symposium on Advanced Wound Care (SAWC) being held April … Continue reading →

Smith Medical Partners, the specialty pharmaceutical subsidiary of H. D. Smith, today announced an exclusive logistics and cold chain services agreement with Cardium Therapeutics, a health sciences and regenerative medicine company, to support its recently launched wound care product, Excellagen™.  … Continue reading →

Friday, Cardium Therapeutics announced Excellagen’s introduction into U.S. markets. Excellagen is a wound care product for dermal wounds, such as diabetic foot ulcers and other types of pressure ulcers. Cardium is focused on the acquisition and development of new bio-medical … Continue reading →

Cardium Therapeutics today presented highlights of financial results for its fourth quarter and fiscal year ended December 31, 2011, and other recent developments and outlook for 2012. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Highlights of 2011 and Recent Developments Initiated market introduction of Cardium’s new Excellagen™ … Continue reading →

Cardium Therapeutics today announced market introduction of its Excellagen™ professional-use, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds. (Photo:  http://photos.prnewswire.com/prnh/20120330/LA79308) (Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Excellagen is a new, FDA-cleared highly-refined fibrillar collagen-based topical … Continue reading →

Nutritional Products International (NPI) and Cardium Therapeutics today announced that MedPodium Nutra-Apps® products are now available on RevNutrition.com. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) The MedPodium Nutra-Apps brand offers easy-to-use dietary supplements that have been formulated to promote personal health and wellness for today’s … Continue reading →

Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium’s lead product candidate, Generx® (Ad5FGF-4) in patients with myocardial ischemia (insufficient blood flow in the heart due to coronary artery … Continue reading →

Cardium Therapeutics  is now making its MedPodium Nutra-Apps® products available across the United States by working with Nutritional Products International (NPI) and InHealth Media. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Nutra-Apps are easy-to-use dietary supplements designed to promote personal health and well being for … Continue reading →